Show simple item record

dc.contributor.authorKumar, Shant
dc.contributor.authorHand, P H
dc.contributor.authorMarsden, Henry B
dc.contributor.authorKumar, Patricia
dc.contributor.authorThor, A
dc.date.accessioned2010-07-27T14:48:52Z
dc.date.available2010-07-27T14:48:52Z
dc.date.issued1991
dc.identifier.citationQuantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours., 11 (4):1657-62 Anticancer Res.en
dc.identifier.issn0250-7005
dc.identifier.pmid1660693
dc.identifier.urihttp://hdl.handle.net/10541/108441
dc.description.abstractA monoclonal antibody, RAP-5, raised against the 21,000d ras-oncogene product, p21, was used in an immunoperoxidase staining procedure to study the expression of p21 in normal children's and foetal kidneys, pre-malignant lesions and benign and malignant childhood renal tumours with good, moderate or poor prognosis. ras-p21 was expressed in both normal and foetal kidneys but its distribution in renal tumours differed markedly (p less than 0.01). A quantitative liquid competition radioimmunoassay (RIA) was used to determine ras-p21 level in tissue homogenates. The results were expressed as pg of ras-p21 per microgram protein of tissue extract. There were significant differences in the levels of ras-p21 among various renal tissue extracts (p less than 0.05). Generally it emerged that the amount of ras-p21 was greater in both malignant renal tumours and foetal kidneys compared to normal kidneys, pre-malignant lesions and benign renal tumours.
dc.language.isoenen
dc.subjectKidney Canceren
dc.subjectBiological Tumour Markersen
dc.subjectWilms Tumouren
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshChild
dc.subject.meshFetus
dc.subject.meshGenes, ras
dc.subject.meshHumans
dc.subject.meshImmunoenzyme Techniques
dc.subject.meshKidney
dc.subject.meshKidney Neoplasms
dc.subject.meshPrecancerous Conditions
dc.subject.meshProto-Oncogene Proteins p21(ras)
dc.subject.meshRadioimmunoassay
dc.subject.meshReference Values
dc.subject.meshTumor Markers, Biological
dc.subject.meshWilms Tumor
dc.titleQuantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital and Holt Radium Institute, Manchester, England.en
dc.identifier.journalAnticancer Researchen
html.description.abstractA monoclonal antibody, RAP-5, raised against the 21,000d ras-oncogene product, p21, was used in an immunoperoxidase staining procedure to study the expression of p21 in normal children's and foetal kidneys, pre-malignant lesions and benign and malignant childhood renal tumours with good, moderate or poor prognosis. ras-p21 was expressed in both normal and foetal kidneys but its distribution in renal tumours differed markedly (p less than 0.01). A quantitative liquid competition radioimmunoassay (RIA) was used to determine ras-p21 level in tissue homogenates. The results were expressed as pg of ras-p21 per microgram protein of tissue extract. There were significant differences in the levels of ras-p21 among various renal tissue extracts (p less than 0.05). Generally it emerged that the amount of ras-p21 was greater in both malignant renal tumours and foetal kidneys compared to normal kidneys, pre-malignant lesions and benign renal tumours.


This item appears in the following Collection(s)

Show simple item record